**Guideline Page and Request** | **Panel Discussion/References** | **Institution Vote**
--- | --- | ---
PAP-10, FOLL-9, and HURT-9 External request: Submission from Novartis Pharmaceuticals Corporation to review data for inclusion of everolimus in combination with sorafenib for the treatment of metastatic differentiated thyroid cancer (DTC). | Based on a review of the data in the noted references and discussion, the panel consensus supported not including everolimus in combination with sorafenib for the treatment of metastatic differentiated thyroid cancer (DTC).  
- Sherman E, Ho A, Fury M et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. Poster presented at presented at American Society of Clinical Oncology; May 29-June 2, 2015: Chicago, IL. Poster 6069. | YES 0  
NO 15  
ABSTAIN 0  
ABSENT 14